- Home
- IRON vs CC Comparison
IRON vs CC Comparison
Compare IRON & CC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- CC
- Stock Information
- Founded
- IRON 2017
- CC 2014
- Country
- IRON United States
- CC United States
- Employees
- IRON N/A
- CC N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- CC Major Chemicals
- Sector
- IRON Health Care
- CC Industrials
- Exchange
- IRON Nasdaq
- CC Nasdaq
- Market Cap
- IRON 1.8B
- CC 1.7B
- IPO Year
- IRON N/A
- CC N/A
- Fundamental
- Price
- IRON $55.86
- CC $13.75
- Analyst Decision
- IRON Strong Buy
- CC Buy
- Analyst Count
- IRON 11
- CC 9
- Target Price
- IRON $92.64
- CC $17.78
- AVG Volume (30 Days)
- IRON 390.2K
- CC 5.1M
- Earning Date
- IRON 08-07-2025
- CC 07-31-2025
- Dividend Yield
- IRON N/A
- CC 2.54%
- EPS Growth
- IRON N/A
- CC N/A
- EPS
- IRON N/A
- CC 0.18
- Revenue
- IRON N/A
- CC $5,788,000,000.00
- Revenue This Year
- IRON N/A
- CC $4.91
- Revenue Next Year
- IRON N/A
- CC $3.82
- P/E Ratio
- IRON N/A
- CC $76.23
- Revenue Growth
- IRON N/A
- CC N/A
- 52 Week Low
- IRON $30.82
- CC $9.13
- 52 Week High
- IRON $68.73
- CC $25.54
- Technical
- Relative Strength Index (RSI)
- IRON 61.10
- CC 69.15
- Support Level
- IRON $52.70
- CC $12.33
- Resistance Level
- IRON $55.26
- CC $13.16
- Average True Range (ATR)
- IRON 2.42
- CC 0.65
- MACD
- IRON 0.01
- CC 0.27
- Stochastic Oscillator
- IRON 92.71
- CC 92.80
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.